Moving to UC, the risk of serious adverse events and serious infections were similar between patients treated with vedolizumab and anti-TNF-α drugs, even though among anti-TNF-α naïve patients, treatment with vedolizumab seemed to be protective from serious adverse events. The gene discussed is TNF; the disease is infection.